Therapeutic uses: specific combinations
The modern picture includes a prescription combination of DXM and bupropion: Auvelity has a US indication for major depressive disorder in adults. In 2026, the FDA added agitation associated with dementia due to Alzheimer’s disease.
CorrectedAccording to the 2026 audit · edition
Evidence and limitations
What was examined: The current label describes a specific combination product and clinical studies supporting its indications. Bupropion increases DXM exposure through CYP2D6 inhibition.
Limits of the conclusion: The conclusion concerns the product composition and indications studied. The label describes DXM’s therapeutic mechanism as unclear.
Sources: Auvelity — current label FDA — new Auvelity indication
Historical paraphrase · FAQ 4.0 · 1997 · §6.8 The FAQ is skeptical about dissociative substances as treatments for depression.
This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §6.8 · Kicking the DXM Habit: What to Do If You are Addicted